Ofev (nintedanib) is a tyrosine kinase inhibitor prescribed to treat idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases with a progressive phenotype. It works by blocking pathways involved in the scarring and fibrosis of lung tissue, helping to slow lung function decline. Ofev is taken orally twice daily with food to improve tolerability. Patients receiving Ofev should be monitored for side effects such as diarrhea, liver enzyme elevations, and risk of bleeding. It is important to follow healthcare provider instructions closely during treatment to manage potential adverse effects and optimize therapy.